Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688088 · ClinicalTrials.gov registry record · Phase 1
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02688088 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 48 participants.
The verdict
NCT02688088, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study is known as a "drug interaction study" and is being done to see how abemaciclib may affect the blood levels of a drug mixture of commonly used drugs (caffeine, warfarin, dextromethorphan, and midazolam) when taken in combination with abemaciclib. Each participant will complete screening and four study periods in a fixed sequence, with the option to continue to receive abemaciclib in a safety extension phase. All participants will complete a safety follow-up.
Interventions
- DRUG Abemaciclib
- DRUG Drug Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-03-08 |
| Est. Completion | 2021-01-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02688088
The ClinicalTrials.gov registry entry for NCT02688088 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abemaciclib is the first listed.
NCT02688088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02688088 about?
NCT02688088 is a clinical study titled "A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body". This study is known as a "drug interaction study" and is being done to see how abemaciclib may affect the blood levels of a drug mixture of commonly used drugs (caffeine, warfarin, dextromethorphan, and midazolam) when taken in combination with abemaciclib. Each participant will complete screening a...
What is the current status of trial NCT02688088?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2016-03-08. Estimated completion is 2021-01-06.
What interventions are being tested in trial NCT02688088?
The interventions under investigation include: Abemaciclib (DRUG), Drug Cocktail (DRUG).
Who is sponsoring clinical trial NCT02688088?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.